Price T Rowe Associates Inc Cytom X Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $42,296 - $79,894	-27,645 Reduced 4.18%	633,418 $1.16 Million
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $3,204 - $5,616	1,200 Added 0.18%	661,063 $1.77 Million
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $10,843 - $20,706	-2,802 Reduced 0.42%	659,863 $2.86 Million
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $110,846 - $164,987	-25,659 Reduced 3.73%	662,665 $3.37 Million
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $6.38 Million - $9.99 Million	-1,007,942 Reduced 59.42%	688,324 $4.36 Million
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $6.66 Million - $9.09 Million	1,009,792 Added 147.1%	1,696,266 $13.1 Million
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $4.44 Million - $5.42 Million	686,474 New	686,474 $4.5 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.